Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F12%3A00003853" target="_blank" >RIV/00216208:11120/12:00003853 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023752:_____/12:43913792

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.eurpsy.2011.08.002" target="_blank" >http://dx.doi.org/10.1016/j.eurpsy.2011.08.002</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.eurpsy.2011.08.002" target="_blank" >10.1016/j.eurpsy.2011.08.002</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression

Popis výsledku v původním jazyce

This position statement will address in an evidence-based approach some of the important issues and controversies of current drug treatment of depression such as the efficacy of antidepressants, their effect on suicidality and their place in a complex psychiatric treatment strategy including psychotherapy. The efficacy of antidepressants is clinically relevant. The highest effect size was demonstrated for severe depression. Based on responder rates and based on double-blind placebo-controlled studies, the number needed to treat (NNT) is 5-7 for acute treatment and four for maintenance treatment. Monotherapy with one drug is often not sufficient and has to be followed by other antidepressants or by comedication/augmentation therapy approaches. Generally, antidepressants reduce suicidality, but under special conditions like young age or personality disorder, they can also increase suicidality. However, under the conditions of good clinical practice, the risk-benefit relationship of treat

Název v anglickém jazyce

Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression

Popis výsledku anglicky

This position statement will address in an evidence-based approach some of the important issues and controversies of current drug treatment of depression such as the efficacy of antidepressants, their effect on suicidality and their place in a complex psychiatric treatment strategy including psychotherapy. The efficacy of antidepressants is clinically relevant. The highest effect size was demonstrated for severe depression. Based on responder rates and based on double-blind placebo-controlled studies, the number needed to treat (NNT) is 5-7 for acute treatment and four for maintenance treatment. Monotherapy with one drug is often not sufficient and has to be followed by other antidepressants or by comedication/augmentation therapy approaches. Generally, antidepressants reduce suicidality, but under special conditions like young age or personality disorder, they can also increase suicidality. However, under the conditions of good clinical practice, the risk-benefit relationship of treat

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FL - Psychiatrie, sexuologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Psychiatry

ISSN

0924-9338

e-ISSN

—

Svazek periodika

27

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

FR - Francouzská republika

Počet stran výsledku

15

Strana od-do

114-128

Kód UT WoS článku

000300397000005

EID výsledku v databázi Scopus

—